

# 1 Sero-monitoring of health care workers reveals complex 2 relationships between common coronavirus antibodies and 3 SARS-CoV-2 severity

4  
5 Sigrid Gouma<sup>1</sup>, Madison E. Weirick<sup>1</sup>, Marcus J. Bolton<sup>1</sup>, Claudia P. Arevalo<sup>1</sup>, Eileen C.  
6 Goodwin<sup>1</sup>, Elizabeth M. Anderson<sup>1</sup>, Christopher M. McAllister<sup>1</sup>, Shannon R. Christensen<sup>1</sup>,  
7 Debora Dunbar<sup>2</sup>, Danielle Fiore<sup>3</sup>, Amanda Brock<sup>4</sup>, JoEllen Weaver<sup>4</sup>, John Millar<sup>5</sup>, Stephanie  
8 DerOhannessian<sup>4,5</sup>, The UPenn COVID Processing Unit<sup>6</sup>, Ian Frank<sup>2</sup>, Daniel J. Rader<sup>4,5</sup>, E. John  
9 Wherry<sup>7</sup>, Scott E. Hensley<sup>1,\*</sup>

10  
11 <sup>1</sup>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,  
12 Philadelphia, PA  
13 <sup>2</sup>Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania,  
14 Philadelphia, PA  
15 <sup>3</sup>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania,  
16 Philadelphia, PA  
17 <sup>4</sup>Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University  
18 of Pennsylvania, Philadelphia, PA  
19 <sup>5</sup>Departments of Genetics and Medicine, Perelman School of Medicine, University of  
20 Pennsylvania, Philadelphia, PA  
21 <sup>6</sup>The UPenn COVID Processing Unit is a unit of individuals from diverse laboratories at the  
22 University of Pennsylvania who volunteered time and effort to enable study of COVID-19  
23 patients during the pandemic. Members are listed in the acknowledgement section.  
24 <sup>7</sup>Institute for Immunology, Perelman School of Medicine, University of Pennsylvania,  
25 Philadelphia, PA

26  
27 \*Corresponding authors email: [hensley@penmedicine.upenn.edu](mailto:hensley@penmedicine.upenn.edu)

## 28 Conflict of Interest Statement:

29 I.F. is a consultant for Gilead Sciences and ViiV Healthcare, and has received research support  
30 from Sanofi Pasteur for work unrelated to this report. E.J.W. has consulting agreements with  
31 and/or is on the scientific advisory board for Merck, Elstar, Janssen, Related Sciences,  
32 Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal  
33 Biosciences. E.J.W. is an inventor on a patent (U.S. patent number 10,370,446) submitted by  
34 Emory University that covers the use of PD-1 blockade to treat infections and cancer. D.J.R. is  
35 on scientific advisory boards for Alnylam, Metrea, Novartis, Pfizer and Verve, is a consultant for  
36 and receives research support from Regeneron for work unrelated to this report, and is a  
37 founder of Vascular Strategies and Staten Biotechnologies. S.E.H. has received consultancy fee  
38 from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report.

39  
40  
41 Keywords: SARS-CoV-2; COVID-19; common coronavirus; OC43; HKU1; health care worker

42 **Abstract**

43 Recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity  
44 upon SARS-CoV-2 infection, however the immunological mechanisms involved are unknown. We  
45 completed serological assays using samples collected from health care workers to identify  
46 antibody types associated with SARS-CoV-2 protection and COVID-19 severity. Rare SARS-  
47 CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with  
48 protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly  
49 reduced in individuals with higher common betacoronavirus ( $\beta$ CoV) antibody titers. Since antibody  
50 titers decline over time after CCV infections, individuals in our cohort with higher  $\beta$ CoV antibody  
51 titers were more likely recently infected with common  $\beta$ CoVs compared to individuals with lower  
52 antibody titers. Therefore, our data suggest that recent  $\beta$ CoV infections potentially limit the  
53 severity of SARS-CoV-2 infections through mechanisms that do not involve cross-reactive  
54 antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses  
55 elicited by recent common  $\beta$ CoV infections transiently reduce disease severity following SARS-  
56 CoV-2 infections.

## 57 **Introduction**

58 SARS-CoV-2 causes heterogenous disease outcomes in different individuals that can range from  
59 asymptomatic infections to critical illness and death (1). It is unknown if prior exposure histories  
60 to common coronaviruses (CCVs) contribute to diverse outcomes following SARS-CoV-2  
61 infections. A study reviewing electronic health records indicated that individuals recently infected  
62 with CCVs were not protected from SARS-CoV-2 infections but experienced less severe disease  
63 upon infection (2). Our group and others have found that some individuals possessed pre-  
64 pandemic antibodies that cross-react to SARS-CoV-2 (3-5), but these cross-reactive antibodies  
65 were not associated with SARS-CoV-2 protection or attenuating COVID-19 severity. Thus, it is  
66 unclear how prior CCV exposures influence outcomes following SARS-CoV-2 infections.

67 Antibody titers to CCVs are elevated after recent CCV infections but then gradually decline  
68 over time (6). Antibody titers to CCVs can therefore serve as an ‘immunological stamp’ that dates  
69 recent CVV infections. Much less is known about the kinetics of T cell responses following CCV  
70 infections and how cellular immunity elicited by past CCV exposures impacts subsequent  
71 encounters with CCVs and SARS-CoV-2. Some individuals possessed SARS-CoV-2-reactive  
72 CD4+ and CD8+ T cells prior to the COVID-19 pandemic (7-11); however, the impact of cellular  
73 immunity elicited by prior common coronavirus infections on SARS-CoV-2 infections is poorly  
74 understood.

75 In this study we established a cohort of 2,043 health care workers and we longitudinally  
76 collected serum samples in the spring and summer of 2020 during the first wave of SARS-CoV-2  
77 activity in Philadelphia, PA. We identified a subset of health care workers who went on to become  
78 infected with SARS-CoV-2 after we collected serum samples. We completed a series of  
79 serological assays to determine if antibodies reactive to SARS-CoV-2 and CCVs were associated  
80 with SARS-CoV-2 protection and COVID-19 severity upon infection.

## 81 **Results**

### 82 *Establishment of a health care worker cohort*

83 We established a prospective cohort of 2,043 health care workers during the spring of 2020 to  
84 monitor SARS-CoV-2 seroprevalence and identify correlates of protection against SARS-CoV-2  
85 infections. We included health care workers at 3 hospitals in the University of Pennsylvania health  
86 system (Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and  
87 Pennsylvania Hospital) who had direct contact with or worked on units with patients, and we  
88 excluded anyone previously diagnosed with COVID-19. Participants were predominantly female  
89 (75.2%), White (82.9%) and non-Hispanic (96.5%). The median age was 36 years (inter quartile

90 range [IQR]: 30-46 years) (**Supplemental Table 1**). Participants of our study were enrolled during  
91 the spring of 2020 when SARS-CoV-2 began widely circulating in Philadelphia (**Figure 1A**).

92 We collected baseline serum samples from each participant between April 13, 2020 and May  
93 20, 2020 (**Figure 1B**). Within 36-48 hours after sample collection, we quantified levels of SARS-  
94 CoV-2 spike receptor binding domain (S-RBD) serum antibodies. We collected NP swabs from  
95 all SARS-CoV-2 S-RBD seropositive participants and we completed SARS-CoV-2 PCR testing to  
96 identify active or recent infections. Participants who were seronegative at the baseline visit were  
97 invited for follow-up visits every 2 weeks until July 2, 2020 and NP SARS-CoV-2 PCR testing was  
98 completed on all participants who seroconverted. In total, we collected 6,897 serum samples  
99 between April 13, 2020 and July 2, 2020 from 2,043 health care workers (**Figure 1B**). This  
100 included 2,043 serum samples collected at a baseline visit, 1,914 samples collected at visit 2,  
101 1,718 samples collected at visit 3, and 1,214 samples collected at visit 4. We also collected serum  
102 samples from 8 participants who were seronegative at their baseline visit and had a positive NP  
103 SARS-CoV-2 PCR test outside of our study before July 20, 2020. Additional serum samples were  
104 collected from seropositive health care workers up to 236 days post-seroconversion to monitor  
105 the longevity of antibody responses following SARS-CoV-2 infection, including one seropositive  
106 participant who had a positive NP SARS-CoV-2 PCR after July 2, 2020.

### 107 *Seroprevalence during the first spring/summer 2020 wave of SARS-CoV-2 infections in* 108 *Philadelphia*

109 We found that 40 of 2,043 healthcare workers (2.0%) in our cohort possessed serum IgG and/or  
110 IgM SARS-CoV-2 S-RBD-reactive antibodies at baseline (**Figure 1C**). Of the 40 seropositive  
111 samples, 17 (42.5%) were IgG<sup>+</sup>/IgM<sup>-</sup>, 7 (17.5%) were IgG<sup>-</sup>/IgM<sup>+</sup>, and 16 (40.0%) were IgG<sup>+</sup>/IgM<sup>+</sup>.  
112 Seropositivity remained consistently low throughout the study period (**Figure 1B**). Out of the 2,003  
113 health care workers who were seronegative at baseline, 15 health care workers (0.7%) became  
114 seropositive on subsequent study visits (**Figure 1C**). Of the 15 health care workers who  
115 seroconverted while enrolled in our study, 5 (33.3%) were IgG<sup>+</sup>/IgM<sup>-</sup> and 10 (66.7%) were  
116 IgG<sup>+</sup>/IgM<sup>+</sup>. As of July 2, 2020, the overall seropositivity rate in our health care workers cohort was  
117 2.7%, which was similar to the 3.2% seroprevalence rate reported for the Philadelphia metro area  
118 and surrounding counties from 13-25 April 2020 (12), but lower than the 6.2% seroprevalence  
119 rate we previously reported in samples collected from parturient women from 4 April-3 June 2020  
120 (13). Consistent with other reports (14, 15), the low seroprevalence within our cohort suggest that  
121 PPE and other precautions taken within our hospitals limited the spread of SARS-CoV-2 infections  
122 of healthcare workers.

123 Of the 40 health care workers who were seropositive at baseline, only 6 (15.0%) were NP  
124 SARS-CoV-2 PCR positive. Since we only enrolled health care workers who did not have a known  
125 or suspected history of COVID-19 diagnosis, most seropositive participants entering our study  
126 likely had prior asymptomatic SARS-CoV-2 infections before the study began. Of the 15 health  
127 care workers who seroconverted after the baseline visit, 12 (80.0%) were SARS-CoV-2 NP PCR  
128 positive.

### 129 *Antibody kinetics after SARS-CoV-2 infection*

130 We stopped collecting blood samples from seronegative participants in July of 2020 after the first  
131 SARS-CoV-2 wave in Philadelphia; however, we continued to collect samples from seropositive  
132 health care workers so that we could measure serum antibody levels within infected individuals  
133 over time. We quantified SARS-CoV-2 S-RBD antibody levels in samples longitudinally collected  
134 from 47 seropositive participants who possessed IgG antibodies, including 33 health care workers  
135 who possessed IgG antibodies to SARS-CoV-2 S-RBD at the first study visit and 14 health care  
136 workers who seroconverted after first sample collection (**Figure 2**). Consistent with previous  
137 reports (16-19), SARS-CoV-2 S-RBD IgG levels remained relatively stable in the serum of the  
138 majority of health care workers (**Figure 2A**). Of the 39 health care workers with samples collected  
139 for 140 days post seroconversion, 33 possessed detectable levels of serum IgG antibodies.  
140 Health care workers with undetectable IgG concentrations at 140 days post seroconversion had  
141 significantly lower peak geometric mean IgG concentrations than health care workers who  
142 possessed IgG antibodies at 140 days post seroconversion (0.66 versus 6.35 arbitrary units/mL;  
143  $p < 0.001$  in unpaired t test on  $\log_2$ -transformed data). In contrast to IgG levels, the longevity of the  
144 IgM antibody response was highly variable among participants (**Figure 2B**). We detected serum  
145 IgM in some participants for multiple weeks, including one participant with detectable IgM up to  
146 168 days post seroconversion. Interestingly, 5 out of 14 participants who seroconverted did not  
147 possess detectable serum IgM at any study visit (**Figure 2B**).

### 148 *Correlates of protection against SARS-CoV-2 infection and disease severity*

149 SARS-CoV-2 circulated at low levels in Philadelphia during the summer of 2020 but infections  
150 increased during the fall of 2020 and the subsequent winter (**Figure 1A**). We invited all  
151 participants to complete an online survey in January 2021 to report SARS-CoV-2 infections since  
152 the last blood draw, and over half of the participants (1,159) completed this survey. For purposes  
153 of this study, we defined infections that occurred during our initial spring/summer sampling period  
154 as 'viral period one' (infections that occurred before July 2, 2020) and infections that occurred  
155 after our initial sampling period as 'viral period two' (infections that occurred after July 2, 2020)

156 **(Figure 1A)**. We analyzed the last spring/summer serum sample collected from participants who  
157 were either infected or not infected during the second viral period to identify specific types of  
158 antibodies that were correlated with protection.

159 Forty-four of the 55 health care workers who were SARS-CoV-2 S-RBD seropositive during  
160 the first wave of SARS-CoV-2 infections responded to our January 2021 survey. Of these 44  
161 participants who had detectable antibodies to the SARS-CoV-2 S-RBD, 1 seropositive participant  
162 (2.3%) reported a PCR-confirmed infection with SARS-CoV-2 during the second viral period in  
163 the fall of 2020. This participant experienced COVID-19 symptoms including cough and difficulty  
164 breathing. This participant entered our study as SARS-CoV-2 seropositive and SARS-CoV-2 PCR  
165 negative, and therefore we could not confirm that this participant had a SARS-CoV-2 infection  
166 during the first wave of virus circulation during the spring of 2020. It is possible that this individual  
167 was not previously infected with SARS-CoV-2 but instead possessed pre-pandemic cross-  
168 reactive S-RBD antibodies, which we have found were present in approximately 0.9% of  
169 individuals before the COVID-19 pandemic began (3). It is also possible that this individual was  
170 SARS-CoV-2 infected in the spring of 2020 and then re-infected with an antigenically distinct  
171 strain of SARS-CoV-2 in the fall of 2020, although we could not investigate this possibility since  
172 we were unable to obtain NP samples from the fall infection for sequencing.

173 Of the 1,115 health care workers who did not have detectable SARS-CoV-2 spike-RBD  
174 antibodies during the spring and summer of 2020 and who responded to our January 2021 online  
175 survey, 68 participants (6.1%) reported a lab-confirmed SARS-CoV-2 infection after the last blood  
176 draw, including 64 symptomatic infections. Two participants were hospitalized during the fall and  
177 winter because of COVID-19 (**Supplemental Table 2**). We completed additional serological  
178 assays using samples collected during the spring and summer of 2020 from the 68 SARS-CoV-2  
179 spike-RBD seronegative individuals who were PCR-confirmed infected during the second viral  
180 period and 68 participants matched by age and sex who did not report SARS-CoV-2 infections  
181 after the last blood draw. This allowed us to evaluate correlates of protection associated with  
182 preventing SARS-CoV-2 infections in individuals who have not been previously exposed to the  
183 virus. We used ELISA to quantify antibodies against the SARS-CoV-2 full length spike (S-FL)  
184 protein and N protein, as well as antibodies against S-FL proteins from CCVs. Consistent with our  
185 previous study (3), we found that pre-infection antibodies reactive to SARS-CoV-2 S-FL protein  
186 and N protein were rare and at similar levels in health care workers who were and were not  
187 infected with SARS-CoV-2 during the second viral period (**Figure 3A**). Similarly, we found that  
188 antibody titers to S-FL from CCVs were not associated with protection from PCR-confirmed  
189 SARS-CoV-2 infections (**Figure 3A**).

190 Next, we compared the relationship of pre-infection antibody levels with disease severity  
191 following SARS-CoV-2 infection using samples collected from SARS-CoV-2 S-RBD seronegative  
192 individuals who became infected during the second viral period. Our analysis included samples  
193 from 4 health care workers who reported asymptomatic SARS-CoV-2 infections and 58  
194 participants who reported symptomatic SARS-CoV-2 infections (6 participants did not include  
195 information about symptoms and were therefore not included in the analyses). We found no  
196 correlation between symptom duration and pre-infection antibody levels reactive to SARS-CoV-2  
197 S-FL and N proteins (**Figure 3B**). In contrast, we found a strong negative association of symptom  
198 duration and pre-infection antibody titers to OC43 and HKU1 S-FL proteins (**Figure 3B**). After  
199 adjusting via multivariate regression for age and sex, individuals with higher OC43 and HKU1 S-  
200 FL antibody titers had significantly fewer symptomatic days following SARS-CoV-2 infection  
201 ( $p=0.004$  and  $p=0.030$ , respectively; **Supplemental Table 3**). There was no correlation between  
202 symptom duration and antibody titers to 229E and NL63 S-FL proteins (**Figure 3B**). This is  
203 interesting since 229E and NL63 are both alphacoronaviruses, whereas SARS-CoV-2, OC43,  
204 and HKU1 are all betacoronaviruses ( $\beta$ CoVs). While we found significant associations between  
205 OC43 and HKU1 antibody titers and SARS-CoV-2 symptom duration, we found few associations  
206 with pre-infection antibody titers and specific symptoms (**Supplemental Figure**). Since antibodies  
207 to CCVs are elevated after CCV infection and then slowly decline over time (6), individuals with  
208 higher OC43 and HKU1 antibody titers in our cohort were more likely recently infected with these  
209 common  $\beta$ CoVs. The mechanism underlying the apparent transient cross-protection between  
210 common  $\beta$ CoV infections and SARS-CoV-2 symptom duration in our cohort is unknown, but  
211 potentially involves cellular immunity since we found no association with pre-existing SARS-CoV-  
212 2-reactive antibodies and symptom duration following SARS-CoV-2 infections.

## 213 **Discussion**

214 In this study we show that SARS-CoV-2 infections among health care workers at the University  
215 of Pennsylvania are relatively uncommon. Our study, along with others (14, 15) suggest that PPE  
216 and other precautions have efficiently limited the spread of SARS-CoV-2 within our hospitals.  
217 Consistent with other studies (16-19), we show that antibody responses elicited by SARS-CoV-2  
218 are long-lived and detectable up to 140 days following infection in the majority of individuals. We  
219 identified one individual in our study who was potentially infected twice with SARS-CoV-2 but it is  
220 unclear if this individual was truly infected during the first wave of SARS-CoV-2 in Philadelphia.  
221 This individual was SARS-CoV-2 S-RBD antibody positive entering the study in the spring of 2020  
222 and it is possible that this participant was not infected during the first SARS-CoV-2 wave but

223 instead possessed pre-pandemic cross-reactive SARS-CoV-2 S-RBD antibodies that were  
224 present in approximately 0.9% of individuals before the pandemic began (3).

225 The primary goals of our study were initially to use serology to monitor asymptomatic and  
226 symptomatic infections of health care workers during the spring/summer of 2020 and to kinetically  
227 measure antibody levels after infection. Since SARS-CoV-2 continued circulating after the first  
228 wave in Philadelphia, we completed additional analyses to determine if antibody levels in serum  
229 samples collected in the summer of 2020 were associated with protection from subsequent  
230 SARS-CoV-2 infections. Consistent with our recent study (3), we found that pre-infection SARS-  
231 CoV-2 S-FL and N antibody levels were not associated with protection from SARS-CoV-2  
232 infection during the fall and winter in individuals who were not infected with SARS-CoV-2 during  
233 the first viral wave. This is consistent with the observation that most pre-pandemic cross-reactive  
234 SARS-CoV-2 antibodies are non-neutralizing (3). Similarly, we found that pre-infection OC43,  
235 HKU1, 229E, and NL63 S-FL antibody titers were not associated with protection from SARS-CoV-  
236 2 infection.

237 Somewhat paradoxically, we found significant negative correlations between pre-infection  
238 OC43 and HKU1 antibody titers and SARS-CoV-2 symptom duration but we did not find  
239 correlations between pre-infection SARS-CoV-2 antibodies and SARS-CoV-2 symptom duration  
240 among individuals infected with SARS-CoV-2 for the first time during the second viral wave.  
241 Individuals with higher OC43 and HKU1 antibody titers experienced shorter duration of symptoms  
242 following SARS-CoV-2 infection. This apparent cross-protection appears to be specific to  $\beta$ CoV  
243 immunity since we found that antibody titers to the HKU1 and 229E alphacoronaviruses were not  
244 associated with reducing SARS-CoV-2 symptom duration. It may seem contradictory that OC43  
245 and HKU1 antibody levels but not SARS-CoV-2 antibody levels are associated with reduced  
246 symptom duration in individuals who are infected with SARS-CoV-2 for the first time. However,  
247 the cross-protection afforded by common  $\beta$ CoVs is likely not mediated by rare antibodies that  
248 cross-react to SARS-CoV-2 proteins. Instead, this protection might be mediated by cellular  
249 immune responses, which can target epitopes that are conserved among common  $\beta$ CoVs and  
250 SARS-CoV-2 (20). Individuals who were more recently infected with common  $\beta$ CoVs have higher  
251 levels of antibodies against these viruses (6), and therefore elevated levels of antibodies against  
252 OC43 and HKU1 may serve as an 'immunological stamp' that dates how recently an individual  
253 was exposed to common  $\beta$ CoVs. Additional studies need to be completed to determine the  
254 temporal relationship between recent  $\beta$ CoV infections and reduced symptom duration following  
255 SARS-CoV-2 infections; however, our data are consistent with a recent electronic health record  
256 study that suggested that recent common coronavirus infections were associated with reducing



257 the severity of COVID-19 (2). It is possible that T cells stimulated from recent  $\beta$ CoV infections  
258 (21) are involved with clearing virus and reducing symptom duration following SARS-CoV-2  
259 infections. It is also possible that recent  $\beta$ CoV infections stimulate rare B cells that are quickly  
260 recalled following SARS-CoV-2 exposures.

261 Moving forward, it is possible that antibody titers to OC43 and HKU1 might be useful for  
262 predicting relative infection risk among individuals who have not yet encountered SARS-CoV-2.  
263 This type of information might be important for prioritizing vaccinations while the vaccine supply  
264 remains limited. One ironic implication of our study is that individuals who have efficiently socially  
265 distanced over the past year are potentially at higher risk of more severe SARS-CoV-2 symptoms  
266 since it is unlikely that these individuals have been recently infected with common  $\beta$ CoVs during  
267 social isolation. Additional studies will be required to fully understand the complex relationship  
268 between CCV immunity and SARS-CoV-2 susceptibility and temporal relationships between viral  
269 infections and cross-protection.

## 270 **Methods**

### 271 **Study population and data collection**

272 Health care workers at 3 hospitals in the University of Pennsylvania health system (Hospital of  
273 the University of Pennsylvania, Penn Presbyterian Medical Center, and Pennsylvania Hospital)  
274 were recruited between April 13, 2020 to May 20, 2020. Only health care workers with direct  
275 contact with patients or who worked on units where patients with COVID-19 received care were  
276 included in this study. We excluded anyone who was previously diagnosed with a SARS-CoV-2  
277 infection. Characteristics of the 2,043 health care workers in our study are reported in  
278 **Supplemental Table 1**. We collected serum samples from each participant and quantified SARS-  
279 CoV-2 S-RBD antibodies by ELISAs within 36-48 hours after sample collection. We collected NP  
280 swabs from all health care workers who possessed SARS-CoV-2 S-RBD IgG and/or IgM  
281 antibodies and we completed SARS-CoV-2 PCR testing on these samples to identify active or  
282 recent infections. Health care workers who were seronegative at baseline visit were invited for  
283 follow-up visits every 2 weeks until 2 July 2020 to identify active SARS-CoV-2 infections  
284 throughout the study period. In addition, we received serum samples from 8 health care workers  
285 who were seronegative at baseline visit and had a positive NP PCR test outside of our study.  
286 Seropositive health care workers were enrolled in a follow-up study to collect additional blood  
287 samples up to 236 days post seroconversion.

288 Participants filled out an online survey at time of enrollment to collect participant  
289 characteristics, including COVID-19 symptom information. A second online survey was sent to all

290 participants in January 2021 to collect information on new SARS-CoV-2 infections that occurred  
291 after the last blood draw. Based in this information, additional SARS-CoV-2 and common  
292 coronavirus ELISAs were completed in a subset of participants to study pre-infection antibodies.  
293 Informed consent was collected from all participants prior to the baseline visit. This study was  
294 approved by the Institutional Review Board of the University of Pennsylvania under IRB #842847.

### 295 **Enzyme-linked immunosorbent assay (ELISA)**

296 ELISAs measuring antibodies against SARS-CoV-2 and against OC43, HKU1, 229E and NL63  
297 were completed as previously described (13). SARS-CoV-2 nucleocapsid (N) protein and OC43,  
298 HKU1, 229E, and NL63 S-FL proteins were purchased (Sino Biological). Plasmids encoding the  
299 SARS-CoV-2 S-FL and the S-RBD were provided by Florian Krammer (Mt. Sinai). SARS-CoV-2  
300 S-FL and S-RBD were produced in 293F cells and purified using Ni-NTA (Qiagen). Each well in  
301 an ELISA plate (Immulon 4 HBX, Thermo Scientific) was coated with 50  $\mu$ L PBS or recombinant  
302 protein (2  $\mu$ g/mL SARS-CoV-2 antigen or 1.5  $\mu$ g/mL OC43 antigen) and plates were incubated  
303 overnight at 4°C. Wells coated with only PBS were used to measure background signal for each  
304 sample. The next day, plates were washed with PBS containing 0.1% Tween-20 (PBS-T) and  
305 incubated for 1 hour with PBS-T supplemented with 3% non-fat milk powder and 0.1% Tween-  
306 20. Heat-inactivated serum samples were diluted in PBS-T supplemented with 1% non-fat milk  
307 powder and 0.1% Tween-20 (dilution buffer). ELISA plates were washed with PBS-T and 50  $\mu$ L  
308 serum dilution was added to each well. After 2 hours of incubation, plates were washed with PBS-  
309 T and 50  $\mu$ L of 1:5,000 diluted goat anti-human IgG-HRP (Jackson ImmunoResearch  
310 Laboratories) or 1:1,000 diluted goat anti-human IgM-HRP (SouthernBiotech) was added to each  
311 well. Plates were incubated for 1 hour and washed with PBS-T before 50  $\mu$ L SureBlue TMB  
312 Substrate (KPL) was added to each well. After 5 minutes, the reaction was stopped by adding 25  
313  $\mu$ L of 250 mM hydrochloric acid. Plates were read at an optical density (OD) of 450 nm using the  
314 SpectraMax 190 microplate reader (Molecular Devices). Monoclonal antibody CR3022 (for  
315 SARS-CoV-2 S and RBD ELISA) or in-house created serum pool (for SARS-CoV-2 N ELISA and  
316 common coronavirus ELISAs) was included on each plate to convert OD values into relative  
317 antibody concentrations. Plasmids to express the CR3022 monoclonal antibody were provided  
318 by Ian Wilson (Scripps).

### 319 **Statistical analysis**

320 Health care workers with serum IgG and/or IgM concentration above 0.48  $\mu$ g/mL in SARS-CoV-  
321 2 S-RBD ELISAs were considered seropositive. This cutoff results in a pre-pandemic cross-

322 reactive rate of 0.6% for IgG and 0.5% for IgM, as was described previously (13). SARS-CoV-2  
323 S-RBD antibody concentrations below this cutoff at 0.48 arbitrary units/mL were assigned a value  
324 of 0.40 arbitrary units/mL. All other antibodies below the limit of detection (0.20 arbitrary units/mL)  
325 were assigned a value of 0.10 arbitrary units/mL. Antibody concentrations were  $\log_2$ -transformed  
326 for analysis and geometric mean concentrations with 95% confidence intervals were reported  
327 unless stated otherwise. Standard descriptive analyses were used as appropriate including the  
328 Chi-squared test, paired and unpaired *t* tests, Mann-Whitney test and one-way ANOVA with  
329 Bonferroni correction to adjust for multiple comparisons. Pre-existing antibody titers were fitted to  
330 symptom durations in days in separate linear models via logistic regression with a logit link  
331 function, adjusting for age and sex. Statistical significance was set at  $p < 0.05$ . Prism version 9  
332 (GraphPad) and R version 3.5.3 were used for analyses.

### 333 **ACKNOWLEDGEMENTS**

334 This work was supported by institutional funds from the University of Pennsylvania and NIH  
335 U19AI082630 (EJW and SEH) and UM1AI069534 (IF). A.B. and J.W. were supported by the NIH  
336 award number UL1TR001878. EMA was supported by the NIH Training in Virology T32 Program  
337 (T32AI007324) and CPA was supported by the NIH Emerging Infectious Diseases T32 Program  
338 (T32AI055400). The content is solely the responsibility of the authors and does not necessarily  
339 represent the official views of the NIH. We thank J. Lurie, J. Embiid, J. Harris, and D. Blitzer and  
340 J. and M. Greenberg for philanthropic support. We would like to thank the UPenn COVID  
341 Processing Unit, who are comprised of individuals from diverse laboratories at the University of  
342 Pennsylvania who volunteered time and effort to enable study of COVID-19 patients during the  
343 pandemic: Sharon Adamski, Zahidul Alam, Mary M. Addison, Katelyn T. Byrne, Aditi Chandra,  
344 Kurt D'Andrea, H el ene C. Descamps, Nicholas Han, Yaroslav Kaminskiy, Shane C. Kammerman,  
345 Justin Kim, Allison R. Greenplate, Jacob T. Hamilton, Nune Markosyan, Julia Han Noll, Dalia K.  
346 Omran, Ajinkya Pattekar, Eric Perkey, Elizabeth M. Prager, Dana Pueschl, Austin Rennels,  
347 Jennifer B. Shah, Jake S. Shilan, Nils Wilhausen, Ashley N. Vanderbeck. We thank F. Krammer  
348 (Mt. Sinai) for sending us the SARS-CoV-2 spike RBD expression plasmids in the early days of  
349 the COVID-19 pandemic, which was critical for initiating our health care worker cohort study  
350 during the spring of 2020.

## References

1. Hu B, Guo H, Zhou P, and Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.* 2021;19(3):141-54.
2. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. *J Clin Invest.* 2021;131(1).
3. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell.* 2021.
4. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science.* 2020;370(6522):1339-43.
5. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science.* 2020;370(6520).
6. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. *Nat Med.* 2020;26(11):1691-3.
7. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature.* 2020;587(7833):270-4.
8. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell.* 2020;181(7):1489-501 e15.
9. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature.* 2020;584(7821):457-62.
10. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science.* 2020;370(6512):89-94.
11. Schulien I, Kemming J, Oberhardt V, Wild K, Seidel LM, Killmer S, et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. *Nat Med.* 2021;27(1):78-85.

12. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med.* 2020.
13. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci Immunol.* 2020;5(49):eabd5709.
14. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. *J Clin Virol.* 2020;128:104437.
15. Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *JAMA.* 2020;324(2):195-7.
16. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science.* 2020;370(6521):1227-30.
17. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *J Infect Dis.* 2020.
18. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science.* 2021;371(6529).
19. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell.* 2021;184(1):169-83 e17.
20. Sette A, and Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat Rev Immunol.* 2020;20(8):457-8.
21. Lipsitch M, Grad YH, Sette A, and Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nat Rev Immunol.* 2020;20(11):709-13.


## Figure legend

**Figure 1.** Seropositive health care workers by study visit in relation to SARS-CoV-circulation in Philadelphia. (A) Number of positive COVID-19 tests in Philadelphia from March 2020 – February 2021 (data retrieved from [opendataphilly.org](https://opendataphilly.org) on 9 March 2021). The first viral period is defined as infections that occurred before July 2, 2020 and the second viral period as infections that occurred after July 2, 2020. (B) Number of health care workers tested by serum collection date, stratified by study visit and seropositivity status. One out of the 9 health care workers with a positive NP SARS-CoV-2 PCR test outside of our study seroconverted after 2 July 2020 and their seropositive sample is therefore not shown in this graph. (C) Seropositive health care workers (n=55) by study visit. The majority of health care workers (n=1988) were seronegative throughout the study period.


**Figure 2.** Antibody kinetics in 47 health care workers following SARS-CoV-2 infection (n=300 samples). IgG (A) and IgM (B) antibodies to the SARS-CoV-2 S-RBD are shown in health care workers who possessed IgG antibodies upon first study visit (n=33) or seroconverted during the study period (n=14). Lines connect samples collected from one individual.

**Figure 3.** Correlation between pre-existing antibody concentrations and reported SARS-CoV-2 infections and duration of COVID-19 symptoms. (A) Pre-existing antibody concentrations in health care workers with (n=68) and without (n=68) SARS-CoV-2 infection after last blood draw. The control group without SARS-CoV-2 infection after last blood draw was matched to the infection group based on age and sex. Antibody concentrations were similar between infected and uninfected individuals ( $p > 0.28$  in unpaired t-tests using  $\log_2$ -transformed antibody concentrations). Antibody concentrations specific to S-RBD are projected on the left Y-axis and values below the cutoff (0.48) are set at 0.40. All other antibody concentrations are projected on the right Y-axis. And values below the limit of detection (0.20) are set at 0.10. Horizontal lines show the geometric mean concentrations and 95% confidence intervals. (B) Pre-existing antibody concentrations in health care workers who reported a PCR-confirmed SARS-CoV-2 infection and had no symptoms (n=4) or indicated symptom duration via an online survey (n=58). Symptom duration was grouped symptoms resolved within 7 days (n=13), symptoms resolved within 1 month (n=32) and symptoms not resolved within 1 month (n=13). Significant p-values ( $< 0.05$ ) are indicated above the graph (one-way ANOVA using  $\log_2$ -transformed antibody concentrations). Horizontal lines show the geometric mean concentrations and 95% confidence intervals. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

A



B



C















Figure 2







**Supplemental Figure.** Correlation between pre-existing antibody concentrations and reported COVID-19-related symptoms in symptomatic (n=64) and asymptomatic (n=4) health care workers with a PCR-confirmed SARS-CoV-2 infection. Significant p-values (<0.05) are indicated above the graph (one-way ANOVA using log<sub>2</sub>-transformed antibody concentrations). Horizontal lines show the geometric mean concentrations and 95% confidence intervals. \* p<0.05.

**Difficulty breathing****Fever****Fatigueess****Loss of taste/smell****Cough****Nausea/vomiting****Diarrhea****Loss of appetite****Muscle/body aches**

○ No symptoms      ● Other symptoms  
 ● Symptom highlighted in the graph

**Supplemental Table 1.** Participant characteristics.

	Total (N=2043)	Seropositive (N=55)	Seronegative (N=1988)	P-value
Age (in years), median (IQR)	36 (30-46)*	34 (29-44)	36 (30-46)*	0.293
Sex, n (%)				0.719
Male	502 (24.6)	17 (30.9)	485 (24.4)	
Female	1536 (75.2)	38 (69.1)	1498 (75.4)	
Other	2 (0.1)	0	2 (0.1)	
Unknown	3 (0.1)	0	3 (0.2)	
Race, n (%)				0.291
Asian	172 (8.4)	2 (3.6)	170 (8.6)	
Black	117 (5.7)	5 (9.1)	112 (5.6)	
White	1694 (82.9)	45 (81.8)	1649 (82.9)	
Other/multiracial	33 (1.6)	1 (1.8)	32 (1.6)	
Unknown	27 (1.3)	2 (3.6)	25 (1.3)	
Ethnicity, n (%)				0.293
Hispanic	71 (3.5)	4 (7.3)	67 (3.4)	
Non-Hispanic	1971 (96.5)	51 (92.7)	1920 (96.6)	
Unknown	1 (<0.1)	0	1 (0.1)	

\* Age was not reported for 1 participant.

**Supplemental Table 2.** Characteristics of 64 participants who had no detectable S-RBD antibodies during the spring and summer of 2020 and reported via the online survey that they had a symptomatic lab-confirmed SARS-CoV-2 infection after the last blood draw.

	<b>Total (N=64)</b>
<hr/>	
Symptoms, n (%)	
Cough	42 (65.6)
Fever or chills	42 (65.6)
Nausea/vomiting	13 (20.3)
Diarrhea	20 (31.3)
Unusual fatigue	51 (79.7)
Loss of taste or smell	47 (73.4)
Difficulty breathing	17 (26.6)
Loss of appetite	34 (53.1)
Muscle/body aches	45 (70.3)
Other	23 (35.9)
<hr/>	
Estimated date of SARS-CoV-2 infection, n (%)	
July 2020	6 (9.4)
August 2020	1 (1.6)
September 2020	0
October 2020	9 (14.1)
November 2020	14 (21.9)
December 2020	30 (46.9)
January 2021	4 (6.3)
<hr/>	
Resolution of symptoms, n (%)	
Within 7 days	13 (20.3)
Within 1 month	32 (50.0)
More than 1 month	13 (20.3)
Unknown	6 (9.4)
<hr/>	
Hospitalization because of COVID-19, n (%)	2 (3.1)
<hr/>	

**Supplemental Table 3.** Effects of log<sub>2</sub> pre-existing antibody titers, age and sex on symptom duration (days) via multivariate regression.

	<b>Estimate</b>	<b>SE</b>	<b>P-value</b>
S-FL	-2.731	2.685	0.313
Age	3.204	2.697	0.240
Sex (male)	5.675	7.964	0.479
N	1.895	2.698	0.485
Age	3.606	2.712	0.189
Sex (male)	6.299	7.997	0.434
OC43	-8.166	2.739	0.004
Age	0.170	2.752	0.951
Sex (male)	4.226	7.498	0.575
HKU1	-5.867	2.630	0.030
Age	2.392	2.644	0.369
Sex (male)	5.559	7.704	0.474
NL63	-2.354	2.683	0.384
Age	3.548	2.697	0.194
Sex (male)	6.218	7.973	0.439
229E	-3.054	2.846	0.288
Age	2.840	2.742	0.305
Sex (male)	8.483	8.255	0.308